Seelos Therapeutics, Inc. Common Stock
SEEL
SEEL was delisted on the 15th of October, 2024.
18 hedge funds and large institutions have $129K invested in Seelos Therapeutics, Inc. Common Stock in 2024 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 12 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
38% less funds holding
Funds holding: 29 → 18 (-11)
92% less capital invested
Capital invested by funds: $1.55M → $129K (-$1.42M)
92% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$67.4K |
| 2 |
Morgan Stanley
New York
|
+$13.7K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.36K |
| 4 |
MWM
Modera Wealth Management
Westwood,
New Jersey
|
+$3.47K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$34 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GJL
Gendell Jeffrey L
|
-$254K |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$224K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$166K |
| 4 |
SFWC
Strategic Family Wealth Counselors
Fairfield,
New Jersey
|
-$17.7K |
| 5 |
Jane Street
New York
|
-$13.6K |
SEEL Hedge Fund Activity: Q2 2024 in Review
18 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q2 2024, worth a combined $129K — down 92% from $1.55M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of SEEL and 1 opened new positions — a net loss of 11 holders — while 4 trimmed existing stakes and 5 added.
The largest buyer was AdvisorShares Investments, adding an estimated $67.4K. The largest seller was Gendell Jeffrey L, exiting entirely with an estimated $254K sold.
- 18 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q2 2024, down from 29 in Q1 2024.
- Funds reported $129K of Seelos Therapeutics, Inc. Common Stock stock for Q2 2024, down 92% quarter-over-quarter.
- 1 fund opened new Seelos Therapeutics, Inc. Common Stock positions in Q2 2024 and 12 closed out, a net change of -11 holders.
- The largest Seelos Therapeutics, Inc. Common Stock buyer in Q2 2024 was AdvisorShares Investments, an estimated $67.4K added.
- The largest Seelos Therapeutics, Inc. Common Stock seller in Q2 2024 was Gendell Jeffrey L, an estimated $254K sold.
Based on aggregated 13F filings for Q2 2024.